Background aims. Human mesenchymal stromal cells derived from Wharton Jelly (hWJ-MSCs) release a broad range of bioactive components, collectively known as the secretome. This secretome includes growth factors, cytokines and extracellular vesicles (EVs).
Secretome derived from mesenchymal stromal cells (MSCs) holds strong therapeutic potential for regenerative medicine. However, the large-scale production of MSC secretome still presents scientific and technical challenges.
Background. Mesenchymal stromal cells exert their immunoregulatory effects through a complex secretome constituted of soluble factors and extracellular vesicles (EVs).
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a dysfunction of the immune system.
Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells.
Extracellular vesicles (EVs) are expected to serve as interesting drug delivery vectors as they may offer unique and new properties for drug delivery.
Despite current management strategies, digestive fistulae remain extremely debilitating complications associated with significant morbidity and mortality, generating a need to develop innovative therapies in these indications.
Extracellular vesicles (EVs) are 50–1000 nm vesicles secreted by virtually any cell type in the body. They are expected to transfer information from one cell or tissue to another in a short- or long-distance way.
Extracellular vesicles (EVs) have emerged as new drug delivery systems as well as a regenerative cell-free effectors going beyond academic research to reach industrial research and development (R&D).
Extracellular vesicles (EVs) are becoming essential actors in bio-therapeutics, as much for their regenerative or immunomodulatory properties as for their potential as cargo delivery vehicles.